Hepatitis B Vaccine Compliance, Serologic Response, and Durability in Adult Thoracic Organ Transplant Recipients
Although less than half of thoracic organ transplant candidates completed HBV vaccine series pretransplant, Heplisav-B provided a higher vaccine completion rate and seroprotection than the 3-dose Recombivax HB. Clinicians should also be aware of the increased loss of HBV seroprotection in thoracic organ transplant recipients with age ≥ 60 years and pretransplant HBsAb between 10 and 100 IU/L. Assessment of seroprotection after HBV vaccination should be prioritized during the pretransplant period.
Authors
- Elena Beam (ORCID: https://orcid.org/0000-0002-5807-2299)
- Priya Sampathkumar (ORCID: https://orcid.org/0000-0002-1467-9582)
- Chia‐Yu Chiu (ORCID: https://orcid.org/0000-0002-5241-3435)
- Holenarasipur R. Vikram (ORCID: https://orcid.org/0000-0002-6391-0349)
- Lisa Brumble (ORCID: https://orcid.org/0000-0001-5761-7309)
- Kymberly D. Watt
Institutions
- Mayo Clinic (US)
- Jacksonville College (US)
- WinnMed (US)
- Mayo Clinic in Florida (US)
- University of Colorado Denver (US)
Publication Details
- Journal
- Clinical Transplantation
- Published
- 2024-09-01
- DOI
- https://doi.org/10.1111/ctr.15464
- Citations
- 6
- Primary Topic
- Hepatitis B Virus Studies
- Type
- article
- Field-Weighted Citation Impact
- 2.32